Intestinal transport characteristics & metabolism of C-glucosyl dihydrochalcone, aspalathin

Molecules

Volumn 22, Issue 4, 2017, Pages

  Bowles, Sandra ^a   Joubert, Elizabeth ^b,c   De Beer, Dalene ^b,c   Louw, Johan ^a,d   Brunschwig, Christel ^e   Njoroge, Mathew ^e   Lawrence, Nina ^e   Wiesner, Lubbe ^e   Chibale, Kelly ^e,f   Muller, Christo ^a,c,d  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b AGRICULTURAL RESEARCH COUNCIL   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d UNIVERSITY OF ZULULAND   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Aspalathin; Bioavailability; Caco 2; Metabolism; Transport

Indexed keywords

ASPALATHIN; CHALCONE DERIVATIVE; PLANT EXTRACT;

ANIMAL; ASPALATHUS; BIOAVAILABILITY; CACO-2 CELL LINE; CHEMISTRY; HUMAN; INTESTINE; INTESTINE ABSORPTION; MOUSE; PERMEABILITY; TRANSPORT AT THE CELLULAR LEVEL; URINE;

ANIMALS; ASPALATHUS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHALCONES; HUMANS; INTESTINAL ABSORPTION; INTESTINES; MICE; PERMEABILITY; PLANT EXTRACTS; URINE;

EID: 85017037390     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules22040554     Document Type: Article

References (50)

1. Joubert, E.; De Beer, D. Rooibos (Aspalathus linearis) beyond the farm gate: From herbal tea to potential phytopharmaceutical. S. Afr. J. Bot. 2011, 77, 869-886. [CrossRef].
2. Muller, C.J.F.; Malherbe, C.J.; Chellan, N.; Yagasaki, K.; Miura, Y.; Joubert, E. Potential of rooibos, its major C-glucosyl flavonoids and Z-2-(D-glucopyranosyloxy)-3-phenylpropenoic acid in prevention of metabolic syndrome. Crit. Rev. Food Sci. Nutr. 2016. [CrossRef] [PubMed].
3. Courts, F.L.; Williamson, G. The C-glycosyl flavonoid, aspalathin, is absorbed, methylated and glucuronidated intact in humans. Mol. Nutr. Food Res. 2009, 53, 1104-1111. [CrossRef] [PubMed].
4. Stalmach, A.; Mullen, W.; Pecorari, M.; Serafini, M.; Crozier, A. Bioavailability of C-linked dihydrochalcone and flavanone glucosides in humans following ingestion of unfermented and fermented rooibos teas. J. Agric. Food Chem. 2009, 57, 7104-7111. [CrossRef] [PubMed].
5. Breiter, T.; Laue, C.; Kressel, G.; Gröll, S.; Engelhardt, U.H.; Hahn, A. Bioavailability and antioxidant potential of rooibos flavonoids in humans following the consumption of different rooibos formulations. Food Chem. 2011, 128, 338-347. [CrossRef] [PubMed].
6. Scheepers, A.; Joost, H.G.; Schurmann, A. The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function. J. Parenter. Enter. Nutr. 2004, 28, 364-371. [CrossRef] [PubMed].
7. Day, A.J.; Cañada, F.J.; Díaz, J.C.; Kroon, P.A.; Mclauchlan, R.; Faulds, C.B.; Plumb, G.W.; Morgan, M.R.; Williamson, G. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett. 2000, 468, 166-170. [CrossRef].
8. Liu, W.; Wang, H.; Meng, F. In silico modeling of aspalathin and nothofagin against SGLT2. J. Theor. Comput. Chem. 2015, 14, 1550056. [CrossRef].
9. White, J.R. Apple trees to sodium glucose co-Transporter inhibitors: A review of SGLT2 inhibition. Clin. Diabetes 2010, 28, 5-10. [CrossRef].
10. Courts, F.L.; Williamson, G. The occurrence, fate and biological activities of C-glycosyl flavonoids in the human diet. Crit. Rev. Food Sci. Nutr. 2013, 8398, 37-41. [CrossRef] [PubMed].
11. Kawano, A.; Nakamura, H.; Hata, S.; Minakawa, M.; Miura, Y.; Yagasaki, K. Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice. Phytomedicine 2009, 16, 437-443. [CrossRef] [PubMed].
12. Son, M.J.; Minakawa, M.; Miura, Y.; Yagasaki, K. Aspalathin improves hyperglycemia and glucose intolerance in obese diabetic ob/ob mice. Eur. J. Nutr. 2013, 52, 1607-1619. [CrossRef].
13. Parrott, N.; Lukacova, V.; Fraczkiewicz, G.; Bolger, M.B. Predicting pharmacokinetics of drugs using physiologically based modeling-Application to food effects. AAPS J. 2009, 11, 45-53. [CrossRef] [PubMed].
14. Kazuno, S.; Yanagida, M.; Shindo, N.; Murayama, K. Mass spectrometric identification and quantification of glycosyl flavonoids, including dihydrochalcones with neutral loss scan mode. Anal. Biochem. 2005, 347, 182-192. [CrossRef] [PubMed].
15. Joubert, E.; Gelderblom, W.C.A.; De Beer, D. Phenolic contribution of South African herbal teas to a healthy diet. Nat. Prod. Commun. 2009, 4, 701-718. [PubMed].
16. Varma, M.V.; Steyn, S.J.; Allerton, C.; El-Kattan, A.F. Predicting clearance mechanism in drug discovery: Extended Clearance Classification System (ECCS). Pharm. Res. 2015, 32, 3785-3802. [CrossRef] [PubMed].
17. Braune, A.; Blaut, M. Deglycosylation of puerarin and other aromatic C-glucosides by a newly isolated human intestinal bacterium. Environ. Microbiol. 2011, 13, 482-494. [CrossRef] [PubMed].
18. Muller, C.J.F.; Joubert, E.; De Beer, D.; Sanderson, M.; Malherbe, C.J.; Fey, S.J.; Louw, J. Acute assessment of an aspalathin-enriched green rooibos (Aspalathus linearis) extract with hypoglycemic potential. Phytomedicine 2012, 20, 32-39. [CrossRef] [PubMed].
19. Jancova, P.; Anzenbacher, P.; Anzenbacherova, E. Phase II drug metabolizing enzymes. Biomed. Pap. 2010, 154, 103-116. [CrossRef].
20. Kreuz, S.; Joubert, E.; Waldmann, K.H.; Ternes, W. Aspalathin, a flavonoid in Aspalathus linearis (rooibos), is absorbed by pig intestine as a C-glycoside. Nutr. Res. 2008, 28, 690-701. [CrossRef] [PubMed].
21. Van der Merwe, J.D.; Joubert, E.; Manley, M.; De Beer, D.; Malherbe, C.J.; Gelderblom, W.C.A. In vitro hepatic biotransformation of aspalathin and nothofagin, dihydrochalcones of rooibos (Aspalathus linearis), and assessment of metabolite antioxidant activity. J. Agric. Food Chem. 2010, 58, 2214-2220. [CrossRef] [PubMed].
22. Gamage, N.; Barnett, A.; Hempel, N.; Duggleby, R.G.;Windmill, K.F.; Martin, J.L.; McManus, M.E. Human sulfotransferases and their role in chemical metabolism. Toxicol. Sci. 2006, 90, 5-22. [CrossRef] [PubMed].
23. Di, L.; Kerns, E.H. Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization; Elsevier Science: Amsterdam, The Netherlands, 2015.
24. Volpe, D.A. Application of method suitability for drug permeability classification. AAPS J. 2010, 12, 670-678. [CrossRef] [PubMed].
25. Lemmer, H.J.R.; Hamman, J.H. Paracellular drug absorption enhancement through tight junction modulation. Expert Opin. Drug Deliv. 2013, 10, 103-114. [CrossRef] [PubMed].
26. Van de Waterbeemd, H.; Camenisch, G.; Folkers, G.; Chretien, J.R.; Raevsky, O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target. 1998, 6, 151-165. [CrossRef] [PubMed].
27. Camenisch, G.; Folkers, G.; Van de Waterbeemd, H. Shapes of membrane permeability-lipophilicity curves: Extension of theoretical models with an aqueous pore pathway. Eur. J. Pharm. Sci. 1998, 6, 321-329. [CrossRef].
28. Thomson, A.B.; Keelan, M.; Thiesen, A.; Clandinin, M.T.; Ropeleski, M.J.; Wild, G. Small bowel review: Part II. Can. J. Gastroenterol. 2001, 15, 446-466. [CrossRef] [PubMed].
29. Lerner, A.; Matthias, T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun. Rev. 2015, 14, 479-489. [CrossRef] [PubMed].
30. Tsukita, S.; Furuse, M.; Itoh, M. Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2001, 2, 285-293. [CrossRef] [PubMed].
31. Furuse, M.; Hirase, T.; Itoh, M.; Nagafuchi, A.; Yonemura, S.; Tsukita, S.; Tsukita, S. Occludin: A novel integral membrane protein localizing at tight junctions. J. Cell Biol. 1993, 123, 1777-1788. [CrossRef] [PubMed].
32. Morita, K.; Furuse, M.; Fujimoto, K.; Tsukita, S. Claudin multigene family encoding four-Transmembrane domain protein components of tight junction strands. Proc. Natl. Acad. Sci. USA 1999, 96, 511-516. [CrossRef] [PubMed].
33. Mandell, K.J.; Babbin, B.A.; Nusrat, A.; Parkos, C.A. Junctional adhesion molecule 1 regulates epithelial cell morphology through effects on beta1 integrins and Rap1 activity. J. Biol. Chem. 2005, 280, 11665-11674. [CrossRef] [PubMed].
34. Ikenouchi, J.; Furuse, M.; Furuse, K.; Sasaki, H.; Tsukita, S.; Tsukita, S. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J. Cell Biol. 2005, 171, 939-945. [CrossRef] [PubMed].
35. Yu, S.H.; Tang, D.W.; Hsieh, H.Y.;Wu, W.S.; Lin, B.X.; Chuang, E.Y.; Sung, H.W.; Mi, F.L. Nanoparticle-induced tight-junction opening for the transport of an anti-Angiogenic sulfated polysaccharide across Caco-2 cell monolayers. Acta Biomater. 2013, 9, 7449-7459. [CrossRef] [PubMed].
36. Jayalakshmi, K.; Ghoshal, U.C.; Kumar, S.; Misra, A.; Roy, R.; Khetrapal, C.L. Assessment of small intestinal permeability using 1H-NMR spectroscopy. J. Gastrointest. Liver Dis. 2009, 18, 27-32.
37. Huang, M.; Du Plessis, J.; Du Preez, J.; Hamman, J.; Viljoen, A. Transport of aspalathin, a rooibos tea flavonoid, across the skin and intestinal epithelium. Phyther. Res. 2008, 22, 699-704. [CrossRef] [PubMed].
38. Shi, J.; Zhu, L.; Li, Y.; Zheng, H.; Yu, J.; Lu, L.; Liu, Z. In vitro study of UGT metabolism and permeability of orientin and isoorientin, two active flavonoid C-glycosides. Drug Metab. Lett. 2016, 10, 101-110. [CrossRef] [PubMed].
39. Hotamisligil, G.S. Inflammation and metabolic disorders. Nature 2006, 444, 860-867. [CrossRef] [PubMed].
40. Lee, W.; Bae, J.S. Anti-inflammatory effects of aspalathin and nothofagin from rooibos (Aspalathus linearis) in vitro and in vivo. Inflammation 2015, 38, 1502-1516. [CrossRef] [PubMed].
41. Han, Z.; Achilonu, M.C.; Kendrekar, P.S.; Joubert, E.; Ferreira, D.; Bonnet, S.L.; Van der Westhuizen, J.H. Concise and scalable synthesis of aspalathin, a powerful plasma sugar-lowering natural product. J. Nat. Prod. 2013, 77, 583-588. [CrossRef] [PubMed].
42. De Beer, D.; Malherbe, C.J.; Beelders, T.; Willenburg, E.L.; Brand, D.J.; Joubert, E. Isolation of aspalathin and nothofagin from rooibos (Aspalathus linearis) using high-performance countercurrent chromatography: Sample loading and compound stability considerations. J. Chromatogr. A 2015, 1381, 29-36. [CrossRef] [PubMed].
43. Hill, A.P.; Young, R.J. Getting physical in drug discovery: A contemporary perspective on solubility and hydrophobicity. Drug Discov. Today 2010, 15, 648-655. [CrossRef] [PubMed].
44. Alelyunas, Y.W.; Pelosi-kilby, L.; Turcotte, P.; Kary, M.; Spreen, R.C. A high throughput dried DMSO Log D lipophilicity measurement based on 96-well shake-flask and atmospheric pressure photoionization mass spectrometry detection. J. Chromatogr. A 2010, 1217, 1950-1955. [CrossRef] [PubMed].
45. Smetanova, L.; Stetinova, V.; Kholova, D.; Kvetina, J.; Smetana, J.; Svoboda, Z. Caco-2 cells and Biopharmaceutics Classification System (BCS) for prediction of transepithelial transport of xenobiotics (model drug: Caffeine). Neuro Endocrinol. Lett. 2009, 30 (Suppl. 1), 101-105. [PubMed].
46. Johnston, K.; Sharp, P.; Clifford, M.N.; Morgan, L. Dietary polyphenols decrease glucose uptake by human intestinal Caco-2 cells. FEBS Lett. 2005, 579, 1653-1657. [CrossRef] [PubMed].
47. Stipanuk, M.H.; Caudill, M.A. Biochemical, Physiological, and Molecular Aspects of Human Nutrition; Elsevier Health Sciences: Amsterdam, The Netherlands, 2013.
48. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 1991, 175, 880-885. [CrossRef].
49. Ingels, F.; Beck, B.; Oth, M.; Augustijns, P. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int. J. Pharm. 2004, 274, 221-232. [CrossRef] [PubMed].
50. Hubatsch, I.; Ragnarsson, E.G.E.; Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2007, 2, 2111-2119. [CrossRef] [PubMed].